Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Revolution Medicines Inc
RVMDCurrent price
38.11 USD
-0.38 USD (-0.99%)
Last closed
38.75 USD
Company
www.revmed.com
ISIN
US76155X1000
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
8 262 184 448 USD
Yield for 12 month
+25.53 %
1Y
3Y
5Y
10Y
15Y
RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 700 Saginaw Drive, Redwood City, CA, United States, 94063
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
73.00 USDP/E ratio
–Dividend Yield
–Current Year
+11 580 000 USD
Last Year
+35 380 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+11 580 000 USD
Last Year
+25 724 000 USD
Current Quarter
–
Last Quarter
-12 775 000 USD
Key Figures RVMD
1 year
3 years
5 years
10 years
EBITDA
-621 556 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-28.56 %
PEG Ratio
–
Return On Equity TTM
-47.18 %
Wall Street Target Price
73.00 USD
Revenue TTM
742 000 USD
Book Value
9.34 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-95.20 %
Dividend Yield
–
Gross Profit TTM
-217 693 000 USD
Earnings per share
-3.66 USD
Diluted Eps TTM
-3.66 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RVMD
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History RVMD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation RVMD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
9 163.65
Price Sales TTM
11 135.02
Enterprise Value EBITDA
-9.71
Price Book MRQ
5.28
Financials RVMD
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RVMD
For 52 weeks
25.60 USD
62.40 USD
50 Day MA
52.15 USD
Shares Short Prior Month
16 351 130
200 Day MA
42.57 USD
Short Ratio
11.01
Shares Short
16 156 619
Short Percent
10.23 %
BeatStart